Table 2 Summary of patient characteristics
Fiscal year | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cases | Total | Cases | Total | Cases | Total | Cases | Total | Cases | Total | Cases | Total | Cases | Total | |
Age (years) (IQR) | 58.5(55.5-72) | 63(55–70) | 65(62–76) | 63(55–70) | 60(59–76) | 63(56–71) | 61(59–63) | 64(56–71) | 64 | 64(56–71) | 63(58–74) | 64(56–72) | 65(57–70) | 65(57–72) |
Gender (female:male) | 3:1 | 3313:681 | 2:1 | 3832:818 | 3:0 | 4229:923 | 2:0 | 4448:1015 | 1:0 | 5346:1156 | 11:2 | 5895:1284 | 13:0 | 5921:1333 |
Disease dutaion (years) (IQR) | 6(4–9) | 11(5–19) | 15(12–36) | 10(5–19) | 13(11–30) | 10( 5–19) | 23.5(15–32) | 9(4–19) | 24 | 10(5–19) | 16(12–20) | 10(5–19) | 20(15–40) | 10(5–19) |
Arthroplastic surgery (IQR) | 0(0–0) | 0(0–0) | 1(0–2) | 0(0–0) | 1(0–4) | 0(0–0) | 2(0–3) | 0(0–0) | 0% | 0(0–0) | 0(0–3) | 0(0–0) | 0(0–1) | 0(0–0) |
Tender joint count (IQR) | 9(1–30) | 3(1–6) | 15(13–16) | 3(1–6) | 1(0–4) | 2(1–6) | 19(4–34) | 2(0–5) | 4 | 2(0–5) | 3(1–9) | 2(0–4) | 2(1–4) | 1(0–3) |
Swollen joint count (IQR) | 2(0–10) | 2(0–5) | 0(0–4) | 2(0–5) | 0(0–2) | 1(0–4) | 3(3–3) | 1(0–3) | 3 | 1(0–4) | 2(0–6) | 1(0–3) | 2(0–5) | 1(0–3) |
MHAQ (IQR) | 1.4(0.35-1.48) | 0.5(0–1) | 2.3(1.3-2.9) | 0.4(0–1) | 1.5(0.88-2) | 0.4(0–1) | 1.55(1–2.1) | 0.4(0–1) | 1.25 | 0.38(0–1) | 1(0.69-1.44) | 0.25(0–0.9) | 1(0.26-1.94) | 0.25(0–0.9) |
CRP (mg/dl) (IQR) | 3.4(0.9-4.2) | 0.59(0.18-1.7) | 2.7(1.75-3.35) | 0.55(0.18-1.57) | 0.47(0.05-0.71) | 0.47(0.18-1.4) | 1.26(1.02-1.5) | 0.41(0.17-1.22) | 1.95 | 0.31(0.13-1.03) | 1.04(0.18-2.78) | 0.28(0.11-0.9) | 2.0(0.14-3.5) | 0.26(0.1-0.76) |
ESR (mm/h) (IQR) | 38.5(14–66) | 37(20–60) | 43(17–77) | 35(19–56) | 23(9–46) | 33(18–55) | 74.5(46–103) | 31(16–51) | 51 | 29(15–49) | 37.5(29–71.3) | 28(14–47) | 55.5(5.5-84.8) | 25(13–45) |
DAS28-CRP (IQR) | 4.15(3.15-6.11) | 3.34(2.45-4.25) | 4.71(4.67-5.38) | 3.35(2.43-4.24) | 2.98(1.13-3.61) | 3.14(2.29-4.06) | 4.93(3.46-6.39) | 2.99(2.12-3.89) | 4.19 | 2.85(2.04-3.75) | 3.32(2.58-4.46) | 2.72(1.94-3.6) | 3.39(2.3-4.78) | 2.55(1.83-3.46) |
Stage1 (%) | 0 | 14.5 | 0 | 15 | 0 | 15.9 | 0 | 17.7 | 0 | 16.6 | 8.3 | 18 | 7.7 | 19.6 |
Stage2 (%) | 100 | 25 | 33.3 | 25.2 | 0 | 25 | 0 | 25.7 | 0 | 25.6 | 0 | 27.2 | 0 | 26.5 |
Stage3 (%) | 0 | 21 | 33.3 | 20.3 | 0 | 19.9 | 50 | 20.4 | 0 | 20.7 | 25 | 19.3 | 15.4 | 19.6 |
Stage4 (%) | 0 | 39.5 | 33.3 | 39.5 | 100 | 39.2 | 50 | 36.2 | 100 | 37.1 | 66.7 | 35.5 | 76.9 | 34.3 |
Class1 (%) | 0 | 25 | 0 | 26.2 | 0 | 26.2 | 0 | 26.9 | 0 | 25.3 | 25 | 26 | 0 | 28.2 |
Class2 (%) | 75 | 52.7 | 0 | 53.4 | 33.3 | 53.3 | 0 | 52.9 | 0 | 52 | 50 | 53.9 | 61.5 | 52.6 |
Class3 (%) | 25 | 19.1 | 66.7 | 17.4 | 66.7 | 17.4 | 100 | 17.5 | 0 | 19.3 | 25 | 16.8 | 38.5 | 16.4 |
Class4 (%) | 0 | 3.2 | 33.3 | 3 | 0 | 3.1 | 0 | 2.7 | 100 | 3.4 | 0 | 3.3 | 0 | 2.8 |
PtPainVAS (IQR) | 5.5(2.3-7.0) | 3.3(1.6-5.5) | 6.1(4–7) | 3.1(1.5-5.3) | 5.5(1.6-6.8) | 3(1.4-5.2) | 5.5(2.5-8.5) | 3(1.3-5.1) | 4.3 | 2.6(1.1-5) | 3.4(1.4-8.3) | 2.6(1.1-5) | 2.25(0.98-4.95) | 2.4(1–4.8) |
PtGVAS (IQR) | 5.7(3–8.4) | 3.5(1.7-5.5) | 6.8(2.3-8.1) | 3.4(1.6-5.3) | 5.9(0.2-7.8) | 3.2(1.5-5.2) | 5.5(2.5-8.5) | 3(1.4-5.1) | 5.3 | 2.8(1.2-5) | 4.7(0.85-7.75) | 2.7(1.2-5) | 3.1(1.85-5.9) | 1.6(0.7-2.9) |
DrGVAS (IQR) | 7(3.4-8.3) | 2.5(1.3-4.1) | 5.2(3.1-7) | 2.4(1.1-4) | 0.7(0.5-3.4) | 2(1–3.5) | 6.15(3.3-9) | 1.8(0.9-3.1) | 2.6 | 1.6(0.6-3) | 3.8(0.8-4.8) | 1.8(0.8-3) | 2.5(1.05-4.4) | 0.25(0–0.88) |
Use of MTX (%) | 33 | 48 | 0 | 53 | 100 | 53.9 | 50 | 47.3 | 0 | 51.1 | 53.8 | 64.3 | 0 | 58.2 |
Use of corticosteroid (%) | 100 | 63 | 100 | 62 | 100 | 64 | 100 | 61 | 100 | 59.1 | 100 | 53 | 84.6 | 53.4 |
Use of biologics (%) | 0 | 2.1 | 0 | 4.3 | 0 | 9 | 0 | 11.7 | 0 | 13.6 | 38.5 | 20 | 0 | 18.6 |